Voyager Therapeutics (VYGR) Stock Price, News & Analysis

Company Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $3.26 to $3.79
• 50-Day Range: $2.72 to $3.60
• 52-Week Range: $2.64 to $9.55
• Volume: 1.84 million shs
• Average Volume: 547,204 shs
• Market Capitalization: $191.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.39
• Consensus Rating: Buy

Voyager Therapeutics Stock Analysis - MarketRank™

Voyager Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 227th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Voyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Voyager Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Voyager Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Voyager Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Voyager Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Voyager Therapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.13% of the float of Voyager Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Voyager Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Voyager Therapeutics has recently increased by 139.54%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Voyager Therapeutics does not currently pay a dividend.

Dividend Growth

Voyager Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.97

Percentage of Shares Shorted

18.13% of the float of Voyager Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Voyager Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Voyager Therapeutics has recently increased by 139.54%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.13

News Sentiment

Voyager Therapeutics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Voyager Therapeutics this week, compared to 4 articles on an average week.

Search Interest

14 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.53% of the stock of Voyager Therapeutics is held by insiders.

Percentage Held by Institutions

48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VYGR Stock Analysis - Frequently Asked Questions

How have VYGR shares performed this year?

Voyager Therapeutics' stock was trading at $5.67 at the beginning of the year. Since then, VYGR stock has decreased by 39.0% and is now trading at $3.46.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its earnings results on Tuesday, May, 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.18. The business had revenue of $6.47 million for the quarter, compared to the consensus estimate of $13.55 million. Voyager Therapeutics had a negative net margin of 126.49% and a negative trailing twelve-month return on equity of 27.36%.

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' top institutional shareholders include Patriot Financial Group Insurance Agency LLC (0.22%), Allspring Global Investments Holdings LLC (0.10%), Ethic Inc. (0.07%) and Privium Fund Management B.V. (0.05%). Insiders that own company stock include Neurocrine Biosciences Inc, Rock Ventures Iii LP Third, Ecor1 Capital, Llc, Robin Swartz, Robert W Hesslein, Todd Alfred Carter and Sandell Jacquelyn Fahey.
View institutional ownership trends.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/30/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VYGR
• CIK: 1640266
• Web: www.voyagertherapeutics.com
• Phone: (857) 259-5340
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Voyager Therapeutics: $13.39
• High Price Target: $30.00
• Low Price Target: $5.73
• Potential Upside/Downside: +287.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65 million
• Net Margins: -126.49%
• Pretax Margin: -125.46%
• Return on Equity: -27.36%
• Return on Assets: -21.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.10
• Quick Ratio: 6.10

Sales & Book Value

• Annual Sales: $80 million
• Price / Sales: 2.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.49 per share
• Price / Book: 0.63

Miscellaneous

• Outstanding Shares: 55,340,000
• Free Float: 52,829,000
• Market Cap: $191.48 million
• Optionable: Optionable
• Beta: 0.85